LinkedIn

Dr. Wang has over 16 years of experience at NIH where she focused on research in cancer immunotherapy biomarker discovery, and was the Director of Molecular Sciences, as well as Acting Section Chief of the Department of Transfusion Medicine. While at NIH, Dr. Wang was responsible for leading the infectious disease and immunogenetics section. During her tenure, Dr. Wang was responsible for overseeing the TTV lab clinical service, leading the immunogenetics lab research to identify genetic traits in humans that could explain the relationship between pathogens and the host, as relevant to cancer and chronic infections. A seasoned veteran in the industry, Dr. Wang has been asked to speak at over 80 conference presentations in her career, primarily on cancer immunology and translational therapy design.

​

Dr. Wang has published in over 237 peer-reviewed articles. Additionally, Dr. Wang has been the Deputy Editor, Associated Editor, and Editorial Board Member of various journals, including the Journal of Translational Medicine, Current Immunology Reviews, Genetic Medicine, Immunotherapy, Clinical and Translational Medicine, and Journal for Immunotherapy of Cancer.

​

Dr. Wang was the President of the Scientific Board of the Melanoma Bridge cancer conference and serves as a scientific advisor to many cancer organizations, such as the Melanoma Bridge, SITC, the Qatar Genome Committee, the Partnership for Accelerating Cancer Therapies, and is the Co-chair for the SITC Biomarkers taskforce. Dr. Wang also serves on the advisory board for a biotech venture capital firm. Dr. Wang currently serves as the Executive Director of Translational Science at Allogene Therapeutics.

Specialties: Biomarker Discovery, Cellular Engineering, Cell Therapies, Translational Research (Bench-to-bedside), and GMP in Cell, Gene Therapy, and Regenerative Medicine